Market Overview

AbbVie Boosts Shire Offer For The 4th Time

Share:
Related
AbbVie's HUMIRA Gets EU Regulator's Positive Opinion To Treat Some Non-Infectious Uveities Types
AbbVie Says Risankizumab More Effective Than Placebo For Crohn's Disease Management
3 Stories To Watch At The Year's Biggest Cancer Conference (Investor's Business Daily)

The next chapter in the saga between AbbVie (NYSE: ABBV) and Shire (NASDAQ: SHPG) was formed Tuesday morning when AbbVie submitted another offer to buy Shire.

The newest offer is 48 percent higher than Shire’s common stock price when the takeover attempt began in April.

The fourth buyout offer for Shire is approximately an 11 percent increase from the previous bid. The new offer stands at £22.44 cash and 0.8568 AbbVie shares for each Shire share, or £51.15 total.

Related Link: Jefferies Raises PT to $45 on AbbVie on Pipeline Visibility

AbbVie CEO Richard Gonzalez commented, “AbbVie has made a compelling offer to Shire that creates immediate and long-term value to shareholders of both companies. We think its shareholders should strongly encourage the Shire board to engage in constructive dialogue with AbbVie.”

Shares of Shire are moving higher in Tuesday’s pre-market trading. The company was last trading at $240.01, 1.1 percent higher than Monday’s close.

Shares of AbbVie are unchanged.

Posted-In: News M&A

 

Related Articles (SHPG + ABBV)

View Comments and Join the Discussion!